Detailed Instructions: In this task, you are given text for US Congressional and California state bills, your task is to generate a summary for this bill.
See one example below:
Problem: SECTION 1. LIABILITY OF BUSINESS ENTITIES PROVIDING USE OF FACILITIES
TO NONPROFIT ORGANIZATIONS.

(a) Definitions.--In this section:
(1) Business entity.--The term ''business entity'' means a
firm, corporation, association, partnership, consortium, joint
venture, or other form of enterprise.
(2) Facility.--The term ''facility'' means any real
property, including any building, improvement, or appurtenance.
(3) Gross negligence.--The term ''gross negligence'' means
voluntary and conscious conduct by a person with knowledge (at
the time of the conduct) that the conduct is likely to be
harmful to the health or well-being of another person.
(4) Intentional misconduct.--The term ''intentional
misconduct'' means conduct by a person with knowledge (at the
time of the conduct) that the conduct is harmful to the health
or well-being of another person.
(5) Nonprofit organization.--The term ''nonprofit
organization'' means--
(A) any organization described in section 501(c)(3)
of the Internal Revenue Code of 1986 and exempt from
tax under section 501(a) of such Code; or
(B) any not-for-profit organization organized and
conducted for public benefit and operated primarily for
charitable, civic, educational, religious, welfare, or
health purposes.
(6) State.--The term ''State'' means each of the several
States, the District of Columbia, the Commonwealth of Puerto
Rico, the Virgin Islands, Guam, American Samoa, the Northern
Mariana Islands, any other territory or possession of the
United States, or any political subdivision of any such State,
territory, or possession.
(b) Limitation on Liability.--
(1) In general.--Subject to subsection (c), a business
entity shall not be subject to civil liability relating to any
injury or death occurring at a facility of the business entity
in connection with a use of such facility by a nonprofit
organization if--
(A) the use occurs outside of the scope of business
of the business entity;
(B) such injury or death occurs during a period
that such facility is used by the nonprofit
organization; and
(C) the business entity authorized the use of such
facility by the nonprofit organization.
(2) Application.--This subsection shall apply--
(A) with respect to civil liability under Federal
and State law; and
(B) regardless of whether a nonprofit organization
pays for the use of a facility.
(c) Exception for Liability.--Subsection (b) shall not apply to an
injury or death that results from an act or omission of a business
entity that constitutes gross negligence or intentional misconduct,
including any misconduct that--
(1) constitutes a crime of violence (as that term is
defined in section 16 of title 18, United States Code) or act
of international terrorism (as that term is defined in section
2331 of title 18) for which the defendant has been convicted in
any court;
(2) constitutes a hate crime (as that term is used in the
Hate Crime Statistics Act (28 U.S.C. 534 note));
(3) involves a sexual offense, as defined by applicable
State law, for which the defendant has been convicted in any
court; or
(4) involves misconduct for which the defendant has been
found to have violated a Federal or State civil rights law.
(d) Superseding Provision.--
(1) In general.--Subject to paragraph (2) and subsection
(e), this Act preempts the laws of any State to the extent that
such laws are inconsistent with this Act, except that this Act
shall not preempt any State law that provides additional
protection from liability for a business entity for an injury
or death with respect to which conditions under subparagraphs
(A) through (C) of subsection (b)(1) apply.
(2) Limitation.--Nothing in this Act shall be construed to
supersede any Federal or State health or safety law.
(e) Election of State Regarding Nonapplicability.--This Act shall
not apply to any civil action in a State court against a business
entity in which all parties are citizens of the State if such State
enacts a statute--
(1) citing the authority of this subsection;
(2) declaring the election of such State that this Act
shall not apply to such civil action in the State; and
(3) containing no other provision.
Solution: Shields a business entity from civil liability relating to any injury or death occurring at a facility of that entity in connection with a use of such facility by a nonprofit organization if: (1) the use occurs outside the scope of business of the business entity; (2) such injury or death occurs during a period that such facility is used by such organization; and (3) the business entity authorized the use of such facility by the organization.
Makes this Act inapplicable to an injury or death that results from an act or omission of a business entity that constitutes gross negligence or intentional misconduct, including misconduct that: (1) constitutes a hate crime or a crime of violence or act of international terrorism for which the defendant has been convicted in any court; or (2) involves a sexual offense for which the defendant has been convicted in any court or misconduct for which the defendant has been found to have violated a Federal or State civil rights law.
Preempts State laws to the extent that such laws are inconsistent with this Act, except State law that provides additional protection from liability. Specifies that this Act shall not be construed to supersede any Federal or State health or safety law.
Makes this Act inapplicable to any civil action in a State court against a business entity in which all parties are citizens of the State if such State, citing this Act's authority and containing no other provision, enacts a statute declaring the State's election that this Act shall not apply to such action in the State.
Explanation: This Bill focuses on shielding business entities from civil liability relating to an injury or death depending on the conditions of injury, hence the generated summary is correct.

Problem: SECTION 1. SHORT TITLE.

This Act may be cited as the ''Doctor-Patient Relationship and
Research Protection Act''.

SEC. 2. FEDERAL COORDINATING COUNCIL FOR COMPARATIVE EFFECTIVENESS
RESEARCH.

(a) Authority.--Paragraph (1) of section 804(c) of title VIII of
division A of the American Recovery and Reinvestment Act of 2009 (42
U.S.C. 299b-8(c)) is amended to read as follows:
''(1) notwithstanding the provisions under the heading
'agency for healthcare research and quality' of this title and
any other provision of law, have full authority to direct and
coordinate all Federal funding of comparative effectiveness
health care research, including such research conducted or
supported by the Departments of Health and Human Services,
Veterans Affairs, and Defense; and''.
(b) Membership.--Subsection (d) of section 804 of title VIII of
division A of the American Recovery and Reinvestment Act of 2009 (42
U.S.C. 299b-8) is amended to read as follows:
''(d) Membership.--
''(1) In general.--The members of the Council shall include
one senior officer or employee from each of the following
agencies:
''(A) The Agency for Healthcare Research and
Quality.
''(B) The Secretary of Health and Human Services.
''(C) The Director of the National Institutes of
Health.
''(D) 20 members, 9 of whom are not full-time
government employees, appointed by the Comptroller
General of the United States as follows:
''(i) 3 members representing patients and
health care consumers.
''(ii) 3 members representing practicing
physicians, including surgeons.
''(iii) 3 members representing agencies
that administer public programs, as follows:
''(I) 1 member representing the
Centers for Medicare & Medicaid
Services who has experience in
administering the program under title
XVIII of the Social Security Act.
''(II) 1 member representing
agencies that administer State health
programs (who may represent the Centers
for Medicare & Medicaid Services and
have experience in administering the
program under title XIX or the program
under title XXI of the Social Security
Act or be a governor of a State).
''(III) 1 member representing
agencies that administer other Federal
health programs (such as a health
program of the Department of Defense
Federal employees health benefits
program under chapter 89 of title 5 of
the United States Code, a health
program of the Department of Veterans
Affairs under chapter 17 of title 38 of
such Code, or a medical care program of
the Indian Health Service or of a
tribal organization).
''(iv) 3 members representing private
payers, of whom at least 1 member shall
represent health insurance issuers and at least
1 member shall represent employers who self-
insure employee benefits.
''(v) 3 members representing
pharmaceutical, device, and technology
manufacturers or developers.
''(vi) 1 member representing nonprofit
organizations involved in health services
research.
''(vii) 1 member representing organizations
that focus on quality measurement and
improvement or decision support.
''(viii) 1 member representing independent
health services researchers.
''(ix) 1 member representing research in
differences in treatment outcomes along the
lines of racial and ethnic background, gender,
and geography.
''(x) 1 member representing research in
treating rural populations.
''(E) Qualifications.--At least half of the members
of the Council shall be physicians or other experts
with clinical expertise.
''(2) Chairman; vice chairman.--The Secretary shall serve
as Chairman of the Council and shall designate a member to
serve as Vice Chairman.''.
(c) Rules of Construction.--Subsection (g) of section 804 of title
VIII of division A of the American Recovery and Reinvestment Act of
2009 (42 U.S.C. 299b-8) is amended to read as follows:
''(g) Rules of Construction.--
''(1) Coverage.--Nothing in this section shall be
construed--
''(A) to permit the Council to mandate or recommend
coverage, reimbursement, or other policies for any
public or private payer; or
''(B) as preventing the Secretary of Health and
Human Services from covering the routine costs of
clinical care received by an individual entitled to, or
enrolled for, benefits under title XVIII, XIX, or XXI
of the Social Security Act in the case where such
individual is participating in a clinical trial and
such costs would otherwise be covered under such title
with respect to the beneficiary.
''(2) Reports and finding.--No report submitted under this
section or research findings disseminated by the Council shall
be construed as mandates, guidelines, or recommendations for
payment, coverage, or treatment.''.
(d) Transparency, Credibility, and Access.--Section 804 of title
VIII of division A of the American Recovery and Reinvestment Act of
2009 (42 U.S.C. 299b-8) is amended by adding at the end the following:
''(h) Transparency, Credibility, and Access.--The Council shall
establish procedures to ensure that the following requirements for
ensuring transparency, credibility, and access are met:
''(1) Public comment period.--
''(A) Comment prior to obligation of funds for
research.--Before any Federal funds may be obligated to
conduct or support comparative effectiveness research,
the Council shall provide for a period of not less than
30 days for the public to comment on the research
proposal.
''(B) Comment after research results published.--
After the publication of the results of research
described in subparagraph (A), the Council shall
provide for a period of 60 days for the public to
comment on such results.
''(C) Transmission of public comments.--The Council
shall ensure the transmission of public comments
submitted under subparagraph (A) to the entity
conducting the research with respect to which the
individual study design is being finalized.
''(2) Additional forums.--The Council shall, in addition to
the public comment period described in paragraph (1), support
forums to increase public awareness and obtain and incorporate
public feedback through media (such as an Internet website) on
the following:
''(A) The identification of comparative
effectiveness research priorities.
''(B) Comparative effectiveness research findings.
''(C) Any other duties, activities, or processes
the Council determines appropriate.
''(3) Public availability.--The Council shall make
available to the public and disclose through the official
public Internet website of the Council, and through other
forums and media the Council determines appropriate, the
following:
''(A) The process and methods for the conduct of
comparative effectiveness research pursuant to this
section, including--
''(i) the identity of the entity conducting
any such research;
''(ii) any links the entity has to industry
(including such links that are not directly
tied to the particular research);
''(iii) draft study designs (including
research questions and the finalized study
design, together with public comments on such
study design and responses to such comments);
''(iv) research protocols (including
measures taken, methods of research, methods of
analysis, research results, and such other
information as the Council determines
appropriate);
''(v) the identity of investigators
conducting such research and any conflicts of
interest of such investigators; and
''(vi) any progress reports the Council
determines appropriate.
''(B) Public comments submitted during each public
comment period under paragraph (1)(A).
''(C) Bylaws, processes, and proceedings of the
Council, to the extent practicable and as the Council
determines appropriate.
''(D) Not later than 60 days after receipt by the
Council of a relevant report or comparative
effectiveness research finding, appropriate information
contained in such report or finding.
''(4) Conflicts of interest.--
''(A) In general.--The Council shall--
''(i) in appointing members to an advisory
panel, and in selecting individuals to
contribute to any peer-review process and for
employment as executive staff of the Council,
take into consideration any conflicts of
interest of potential appointees, participants,
and staff; and
''(ii) include a description of any such
conflicts of interest and conflicts of interest
of Council members in an annual report to the
Congress, except that, in the case of
individuals contributing to any such peer
review process, such description shall be in a
manner such that those individuals cannot be
identified with a particular research project.
''(B) Definition.--In this subsection, the term
'conflict of interest' means associations, including
financial and personal, that may be reasonably assumed
to have the potential to bias an individual's decisions
in matters related to the Council or the conduct of the
comparative effectiveness research.''.

SEC. 3. APPLICATION OF FEDERALLY FUNDED CLINICAL COMPARATIVE
EFFECTIVENESS RESEARCH.

(a) Limitation on CMS.--The Administrator of the Centers for
Medicare & Medicaid Services may not use federally funded clinical
comparative effectiveness research data to make coverage determinations
under title XVIII of the Social Security Act for medical treatments,
services, and items on the basis of cost.
(b) Requirement for Implementation.--Federally funded clinical
comparative effectiveness research and related evaluation and
communication activities shall reflect the principle that clinicians
and patients should have the best available evidence upon which to make
choices in health care items and services, in providers, and in health
care delivery systems, recognizing that patient subpopulations and
patient and physician preferences may vary.
(c) Appeals of Certain Medicare Coverage Determinations.--In the
case of a national or local coverage determination under title XVIII of
the Social Security Act that has been made utilizing federally funded
comparative effectiveness research, an individual entitled to benefits
under such title shall--
(1) be an eligible requester under section 1869(h)(1)(B) of
such Act in relation;
(2) have expedited access (as specified by the Secretary)
to coverage determinations, redeterminations, and appeals
relating to such determinations; and
(3) have full access to all administrative or judicial
review under section 1869 of such Act with respect to such
determinations.
(d) Rule of Construction.--Nothing in this Act or the amendments
made by this Act shall be construed to require coverage of any drug,
biological product, device, or treatment that has been determined by
the Food and Drug Administration to be unsafe.
(e) Disaggregation of Research Results.--No Federal funds may be
made available to any person for any federally funded clinical
comparative effectiveness research, unless the person agrees to ensure
that, whenever possible, the methodology and research protocols will
include variables that not only measure, but can be disaggregated to
analyze and identify, any differences along the lines of racial and
ethnic background, gender, and geography that may exist among and
within patient subpopulations.
(f) Definitions.--In this section:
(1) The term ''federally funded clinical comparative
effectiveness research'' means research that--
(A) evaluates and compares the clinical
effectiveness, risks, and benefits of 2 or more medical
treatments, services, and items; and
(B) is conducted or supported in accordance with
provisions of title VIII of division A of the American
Recovery and Reinvestment Act of 2009 or with the use
of other Federal funds.
(2) The term ''medical treatments, services, and items''
means health care interventions, protocols for treatment,
procedures, medical devices, diagnostic tools, pharmaceuticals
(including drugs and biologicals), and any other processes or
items being used in the treatment and diagnosis of, or
prevention of illness or injury in, patients.
(3) The term ''patient subpopulations'' means populations
of patients of different racial and ethnic backgrounds,
genders, and geographic locations.
Solution:
Doctor-Patient Relationship and Research Protection Act - Amends the American Recovery and Reinvestment Act of 2009 to: (1) expand the membership of the Federal Coordinating Council for Comparative Effectiveness Research; and (2) require the Council to provide for a public comment period prior to obligating funds for comparative effectiveness research, support increased public awareness of such research, and identify conflicts of interest in appointing members of the Council.

Prohibits the Administrator of the Centers for Medicare & Medicaid Services from using federally funded clinical comparative effectiveness research data to make coverage determinations under Medicare for medical treatments, services, and items on the basis of cost.

Provides for expedited appeals of Medicare coverage determinations using federally funded comparative effectiveness research.

Denies federal funding for clinical comparative effectiveness research that does not consider racial, ethnic, gender, and geographic differences within patient subpopulations.